Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1903 1
1918 1
1942 1
1953 1
1954 1
1957 2
1959 1
1963 1
1970 1
1973 1
1974 2
1975 2
1976 1
1977 2
1978 6
1979 8
1980 7
1981 4
1982 7
1983 6
1984 6
1985 3
1986 5
1987 10
1988 1
1989 10
1990 12
1991 13
1992 13
1993 14
1994 10
1995 7
1996 5
1997 12
1998 12
1999 15
2000 13
2001 13
2002 14
2003 11
2004 19
2005 21
2006 33
2007 23
2008 27
2009 23
2010 16
2011 15
2012 19
2013 23
2014 25
2015 24
2016 23
2017 28
2018 24
2019 29
2020 43
2021 63
2022 45
2023 39
2024 32
2025 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

790 results

Results by year

Filters applied: . Clear all
Page 1
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Sehn LH, et al. Among authors: mcmillan a. J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6. J Clin Oncol. 2020. PMID: 31693429 Free PMC article. Clinical Trial.
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.
Sehn LH, Hertzberg M, Opat S, Herrera AF, Assouline S, Flowers CR, Kim TM, McMillan A, Ozcan M, Safar V, Salles G, Ku G, Hirata J, Chang YM, Musick L, Matasar MJ. Sehn LH, et al. Among authors: mcmillan a. Blood Adv. 2022 Jan 25;6(2):533-543. doi: 10.1182/bloodadvances.2021005794. Blood Adv. 2022. PMID: 34749395 Free PMC article. Clinical Trial.
A new warhead in lymphoma therapy?
McMillan A. McMillan A. Blood. 2021 May 13;137(19):2568-2570. doi: 10.1182/blood.2020009782. Blood. 2021. PMID: 33983420 Free PMC article. No abstract available.
3D Bioprinting in Otolaryngology: A Review.
McMillan A, McMillan N, Gupta N, Kanotra SP, Salem AK. McMillan A, et al. Adv Healthc Mater. 2023 Jul;12(19):e2203268. doi: 10.1002/adhm.202203268. Epub 2023 Mar 31. Adv Healthc Mater. 2023. PMID: 36921327 Free PMC article. Review.
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, Wu HT, Balcioglu M, Sethi H, Scott D, Foran J, McMillan A, Ford JM, Telli ML. Gruber JJ, et al. Among authors: mcmillan a. Nat Cancer. 2022 Oct;3(10):1181-1191. doi: 10.1038/s43018-022-00439-1. Epub 2022 Oct 17. Nat Cancer. 2022. PMID: 36253484 Free PMC article. Clinical Trial.
HIV in prisons.
McMillan A. McMillan A. BMJ. 1988 Oct 8;297(6653):873-4. doi: 10.1136/bmj.297.6653.873. BMJ. 1988. PMID: 3140962 Free PMC article. No abstract available.
Antibody-drug conjugates for multiple myeloma.
McMillan A, Warcel D, Popat R. McMillan A, et al. Expert Opin Biol Ther. 2021 Jul;21(7):889-901. doi: 10.1080/14712598.2020.1802422. Epub 2020 Aug 12. Expert Opin Biol Ther. 2021. PMID: 32729730 Review.
Quantum rangefinding.
Frick S, McMillan A, Rarity J. Frick S, et al. Among authors: mcmillan a. Opt Express. 2020 Dec 7;28(25):37118-37128. doi: 10.1364/OE.399902. Opt Express. 2020. PMID: 33379552 Free article.
790 results